Details of the Drug | DrugMAP

General Information of Drug (ID: DMC4HT7)

Drug Name

NK100

Indication

Disease Entry	ICD 11	Status	REF
Acute myelogenous leukaemia	2A41	Phase 1	[1]
Aggressive cancer	2A00-2F9Z	Phase 1	[2]
------------------------------------------------------------------------------------

Drug Type

Cell therapy

Cross-matching ID

TTD ID: D2CR0K

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

References

1	ClinicalTrials.gov (NCT03081780) Open Label Dose Escalation Trial of an Adaptive Natural Killer (NK) Cell Infusion (FATE-NK100) With Subcutaneous IL-2 in Adults With Refractory or Relapsed Acute Myelogenous Leukemia (AML). U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT03319459) FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors. U.S.National Institutes of Health.